UNIVERSITY HEALTH NETWORK
and Dr. Fei-Fei Liu
SENESCO TECHNOLOGIES, INC.
This Agreement is made as of November 6, 2003 ("Effective Date") between the following parties: the University
Health Network, located at 610 University Avenue, Suite 7-504, Toronto, Ontario M5G 2M9 (hereinafter
"UHN"), Senesco Technologies, Inc., a New Jersey Corporation having a principal place of business at 303
George Street, Suite 420, New Brunswick, NJ 08901 (hereinafter referred to as "Senesco"), and Dr. Fei-Fei Liu
(hereinafter referred to as the "Principal Investigator").
WHEREAS Senesco has conceived of, developed and is continuing to develop proprietary technology relating to
initiation factor eIF5A and DHS and is the owner of proprietary rights thereto, including patent applications filed
thereon on a worldwide basis;
WHEREAS UHN maintains laboratories directed by the Principal Investigator; and
WHEREAS Senesco wishes to fund research performed by Principal Investigator relating to the evaluation of
potential efficacy of elF5A and DHS in human nasopharyngeal carcinoma.
NOW THEREFORE, in consideration of the mutual covenants herein contained, the parties hereby agree as
1.1 "Budget" shall mean the budget prepared by UHN and agreed to by Senesco to support the work to be
performed under the Research Plan in Each Research Year, attached hereto as Schedule B.
1.2 "Confidential Information" shall mean all terms of this Agreement, all Inventions, Invention disclosure reports,
Research Information and Research Information reports as well as all information Exchanged between the parties
pursuant to the Research Plan, including all technical information, ideas, data, compounds, molecules, cell lines,
techniques, methods, processes, uses, composites, skills, trade secrets, and business and marketing information,
as further defined in Article VII herein.
1.3 "Field" shall mean products relating to the treatment, prevention, or detection/diagn